Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMD NASDAQ:AIMD NASDAQ:BTAI NASDAQ:CYCN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.25$0.07▼$5.48$2.92M2.074.87 million shs22.99 million shsAIMDAinos$2.46-5.4%$2.86$2.00▼$5.00$10.90M2.275,391 shs33,129 shsBTAIBioXcel Therapeutics$1.37+4.6%$1.73$1.17▼$16.72$7.93M0.05340,166 shs109.14 million shsCYCNCyclerion Therapeutics$2.57-3.2%$3.07$1.27▼$9.47$8.51M1.6856,861 shs21,239 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%-81.09%-96.42%AIMDAinos-5.38%-4.65%-22.88%-8.89%-24.89%BTAIBioXcel Therapeutics+4.58%-24.31%-29.02%-23.03%-92.35%CYCNCyclerion Therapeutics-3.21%-10.31%-22.27%-18.31%-29.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFMDAffimed2.641 of 5 stars4.00.00.04.30.00.01.3AIMDAinos0.88 of 5 stars0.05.00.00.00.01.70.6BTAIBioXcel Therapeutics3.6038 of 5 stars3.32.00.04.50.61.70.6CYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 2.00Hold$3.621,895.87% UpsideAIMDAinos 0.00N/AN/AN/ABTAIBioXcel Therapeutics 2.67Moderate Buy$42.603,009.49% UpsideCYCNCyclerion Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AFMD, AIMD, BTAI, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025AFMDAffimedCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025AFMDAffimedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/13/2025AFMDAffimedLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025AFMDAffimedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$11.00 ➝ $0.105/13/2025AFMDAffimedLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$5.00 ➝ $0.39(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K3.33N/AN/A$4.19 per share0.04AIMDAinos$20K515.37N/AN/A$5.51 per share0.45BTAIBioXcel Therapeutics$2.27M3.66N/AN/A($30.01) per share-0.05CYCNCyclerion Therapeutics$2M4.12N/AN/A$3.27 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%9/1/2025 (Estimated)AIMDAinos-$14.86M-$6.45N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)BTAIBioXcel Therapeutics-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)CYCNCyclerion Therapeutics-$3.06M-$1.16N/A∞N/AN/A-34.02%-30.68%8/6/2025 (Estimated)Latest AFMD, AIMD, BTAI, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BTAIBioXcel Therapeutics-$2.30N/AN/AN/A$0.21 millionN/A5/12/2025Q1 2025AIMDAinosN/A-$1.05N/A-$0.21N/A$0.11 million5/12/2025Q1 2025BTAIBioXcel Therapeutics-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/AAIMDAinosN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93AIMDAinos0.842.001.91BTAIBioXcel TherapeuticsN/A1.481.45CYCNCyclerion TherapeuticsN/A4.214.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%AIMDAinosN/ABTAIBioXcel Therapeutics30.68%CYCNCyclerion Therapeutics75.62%Insider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%AIMDAinos10.39%BTAIBioXcel Therapeutics21.20%CYCNCyclerion Therapeutics34.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionOptionableAIMDAinos404.19 million3.76 millionNot OptionableBTAIBioXcel Therapeutics906.06 million4.77 millionOptionableCYCNCyclerion Therapeutics303.21 million2.11 millionNo DataAFMD, AIMD, BTAI, and CYCN HeadlinesRecent News About These CompaniesCyclerion Therapeutics files $25M mixed securities shelfFebruary 5, 2025 | markets.businessinsider.com3 US Penny Stocks With Market Caps Over $10M To ConsiderFebruary 5, 2025 | finance.yahoo.comCyclerion Therapeutics Inc (CYCN) Surge: Analyzing Today’s Price IncreaseFebruary 3, 2025 | bovnews.comBLooking Into Cyclerion Therapeutics's Recent Short InterestJanuary 3, 2025 | benzinga.comCyclerion Therapeutics announces update on next stage of growthDecember 18, 2024 | markets.businessinsider.comCyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company GrowthDecember 17, 2024 | finance.yahoo.comCyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company GrowthDecember 17, 2024 | globenewswire.comWhy Did Cyclerion Therapeutics Inc (CYCN) Stock Rise 294.41% to $6.35?December 5, 2024 | bovnews.comBCyclerion Therapeutics Inc (CYCN) Stock: Analyzing Its Quiet PowerNovember 30, 2024 | bovnews.comBCyclerion Therapeutics Inc (CYCN) Stock: Greater Than Its Current Valuation?November 28, 2024 | bovnews.comBCyclerion Therapeutics Inc (CYCN) Stock Trading RecapNovember 19, 2024 | bovnews.comBCyclerion Therapeutics (NASDAQ:CYCN) Stock Quotes, Forecast and News SummaryNovember 16, 2024 | benzinga.comRegina Graul, Ph.D., Promoted to Chief Executive OfficerAugust 7, 2024 | globenewswire.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024May 8, 2024 | investorplace.comSage Therapeutics Stock (NASDAQ:SAGE), Quotes and News SummaryApril 28, 2024 | benzinga.comCyclerion Therapeutics Inc Ordinary Shares CYCNApril 21, 2024 | morningstar.comMCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023April 5, 2024 | investorplace.comCyclerion Therapeutics Inc (CYCN)March 6, 2024 | investing.comCyclerion Therapeutics, Inc. (CYCN)February 29, 2024 | uk.finance.yahoo.comCyclerion Therapeutics Stock (NASDAQ:CYCN) Dividends: History, Yield and DatesFebruary 23, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAFMD, AIMD, BTAI, and CYCN Company DescriptionsAffimed NASDAQ:AFMDAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Ainos NASDAQ:AIMD$2.46 -0.14 (-5.38%) As of 08/1/2025 03:59 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.BioXcel Therapeutics NASDAQ:BTAI$1.37 +0.06 (+4.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.38 +0.01 (+0.73%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Cyclerion Therapeutics NASDAQ:CYCN$2.56 -0.09 (-3.21%) Closing price 08/1/2025 03:49 PM EasternExtended Trading$2.64 +0.08 (+3.12%) As of 08/1/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
